舒泰神（300204）(300204.SZ)发布公告，持股5%以上股东香塘集团有限公司(以下简称"香塘集团")计划 自本公告披露之日起15个交易日后的3个月内，以大宗交易方式减持股份不超过477.77万股，占公司总 股本的1%；以集中竞价方式减持股份不超过477.77万股，占公司总股本的1%。 ...

智通财经APP讯，舒泰神(300204.SZ)发布公告，持股5%以上股东香塘集团有限公司(以下简称"香塘集 团")计划自本公告披露之日起15个交易日后的3个月内，以大宗交易方式减持股份不超过477.77万股， 占公司总股本的1%；以集中竞价方式减持股份不超过477.77万股，占公司总股本的1%。 ...

Group 1: Company Announcements - KWH Holdings announced that its controlling shareholder is planning to transfer shares, which may lead to a change in control. The stock will be suspended from trading for up to 2 days starting August 18, 2025 [2] - New Natural Gas announced that its overseas subsidiary, Zhongneng Holdings, plans to conduct a rights issue based on a 1-for-2 ratio, raising approximately HKD 239 million for project expenses. This will involve a capital restructuring that does not affect shareholder equity [3] - Lianhong New Science plans to absorb its wholly-owned subsidiary, Lianhong Chemical, to enhance management efficiency and reduce costs. This merger will not impact the company's financial status [4] Group 2: Financial Performance - Shengyi Electronics reported a 91% increase in revenue to CNY 3.769 billion and a 452% increase in net profit to CNY 531 million for the first half of 2025, proposing a cash dividend of CNY 0.3 per 10 shares [7] - Landun Optoelectronics experienced a 27.26% decline in revenue to CNY 186 million and a net loss of CNY 35.071 million in the first half of 2025, proposing a cash dividend of CNY 0.05 per 10 shares [9] - Tianjin Pharmaceutical reported a 1.91% decrease in revenue to CNY 4.288 billion but a 16.97% increase in net profit to CNY 775 million, proposing a cash dividend of CNY 2.1 per 10 shares [10] - Electric Science Digital's revenue increased by 7.56% to CNY 4.855 billion, but net profit fell by 19.33% to CNY 108 million, proposing a cash dividend of CNY 0.6 per 10 shares [11] - Tibet Pharmaceutical's revenue grew by 2.23% to CNY 1.651 billion, but net profit decreased by 8.96% to CNY 567 million, proposing a cash dividend of CNY 8.81 per 10 shares [12] - Jinwei Co. reported a 19.62% increase in net profit to CNY 253 million, proposing a cash dividend of CNY 2 per 10 shares [13] - Puyang Co. saw a 48.26% decline in net profit to CNY 68.903 million despite a 3.57% increase in revenue to CNY 2.794 billion [14] - Tongguan Copper Foil turned a profit with a net income of CNY 34.954 million, up from a loss, on revenue of CNY 2.997 billion, a 44.80% increase [15] - Jizhong Energy reported a 27.87% decline in revenue to CNY 7.293 billion and a 65.24% drop in net profit to CNY 348 million [16] - Botong Co. achieved a 42.95% increase in net profit to CNY 13.333 million, with revenue of CNY 149 million, a 5.23% increase [17] - Jinwo Co. reported a 94% increase in net profit to CNY 25.469 million, with revenue of CNY 614 million, a 7.96% increase [18] - Stone Technology's revenue increased by 78.96% to CNY 7.903 billion, but net profit fell by 39.55% to CNY 678 million [19] - North Car Blue Valley reported a revenue increase of 154.38% to CNY 9.517 billion but a net loss of CNY 2.308 billion [20] Group 3: Shareholder Actions - Shuyatong announced that its major shareholder plans to reduce its stake by up to 2% within three months [21] - Western Gold announced that a shareholder plans to reduce its stake by up to 1% [22] - Kang Enbei announced a plan to reduce its stake by up to 1% [23] - Changchun Yidong announced that a major shareholder plans to reduce its stake by up to 2.97% [24] Group 4: Financing and Contracts - Anshuo Information plans to raise up to CNY 600 million through a private placement for various projects [24] - China National Materials International signed an EPC contract for a cement production line in Saudi Arabia worth USD 298 million [25] - Yinlong Co. signed a labor subcontracting contract worth CNY 108 million [25] - *ST Songfa signed two procurement framework contracts for ship steel plates worth approximately CNY 3.371 billion [25]

人民财讯8月15日电，舒泰神（300204）8月15日晚间公告，公司持股7.68%的股东香塘集团有限公司(简 称"香塘集团")，计划15个交易日后的3个月内，以大宗交易方式减持股份不超过477.77万股，占公司总 股本的1%；以集中竞价方式减持股份不超过477.77万股，占公司总股本的1%。 ...

舒泰神公告，持股7.68%的股东香塘集团拟因自身资金需求，自公告披露之日起15个交易日后的3个月 内即2025年9月8日至2025年12月7日，通过大宗交易方式减持不超477.77万股，占1%；通过集中竞价方 式减持不超477.77万股，占1%。 ...

南方财经8月15日电，舒泰神公告称，公司持股5%以上股东香塘集团有限公司计划自本公告披露之日起 15个交易日后的3个月内，以大宗交易和集中竞价方式分别减持公司股份不超过477.77万股，合计占公 司总股本的2%。 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-045 舒泰神（北京）生物制药股份有限公司 关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东香塘集团有限公司保证信息披露内容的真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1、股东名称：香塘集团有限公司； 2、股东持股情况：截至本公告日，香塘集团持有公司股份 3,669.5008 万股， 占公司有表决权总股本的 7.68%，其中：持有有限售条件股份 0 股，持有无限售 条件股份 3,669.5008 万股。 二、本次减持计划的主要内容 1、减持原因：自身资金需求； 2、股份来源：公司首次公开发行股票上市前持有的公司股份（含该等股份 因资本公积金转增股本而相应增加的股份）； 3、计划减持股份数量及比例：计划通过大宗交易方式减持股份不超过 477.77 特别提示： 1、持舒泰神（北京）生物制药股份有限公司（以下简称"公司"或"舒泰 神"）股份 3,669.5008 万股（占公司总股本的 7.68%）的持股 5%以上股东香塘集 团有限公司（以下简称"香塘集团 ...

Core Insights - Shuyatian (300204) reported a closing price of 50.98 yuan on August 14, 2025, with a 2.35% increase and a turnover rate of 3.84% [1] - The company experienced a total revenue of 63.21 million yuan in Q1 2025, a year-on-year decrease of 33.45%, while net profit attributed to shareholders was 2.34 million yuan, a year-on-year increase of 38.05% [1] Financial Performance - Total revenue for Q1 2025: 63.21 million yuan, down 33.45% year-on-year [1] - Net profit for Q1 2025: 2.34 million yuan, up 38.05% year-on-year [1] - Non-recurring net profit: 3.38 million yuan, up 23.93% year-on-year [1] - Current ratio: 1.590, quick ratio: 1.403, debt-to-asset ratio: 18.89% [1] Market Activity - Main capital inflow: 61.01 million yuan, accounting for 6.76% of transaction volume [1] - Large single net inflow: 5.59 million yuan, accounting for 6.2% of transaction volume [1] - Small single net outflow: 2.90 million yuan, accounting for 3.21% of transaction volume [1] Company Background - Shuyatian (Beijing) Biopharmaceutical Co., Ltd. was established in 2002 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 4.78 billion yuan and has made investments in 16 enterprises [2] - The company holds 249 trademark registrations and 118 patent registrations, along with 304 administrative licenses [2]

Core Viewpoint - The company has been under continuous regulatory scrutiny for three consecutive times, but it has not received any official notification or explanation regarding the specific reasons for this situation [1] Group 1 - The company responded to an investor inquiry about the reasons for the ongoing regulatory extensions, indicating a lack of clarity on the matter [1] - The company suggested that investors consult their brokerage firms for more information regarding the risk warning information, as it is published by the brokerage where the investor holds their trading account [1] - The company expressed gratitude for the investor's interest and concern [1]

Group 1 - As of August 12, 2025, the stock price of Shuyou Shen is reported at 49.85 yuan, down by 2.15 yuan, a decline of 4.13% from the previous trading day [1] - The stock reached a high of 52.79 yuan and a low of 49.54 yuan during the trading session, with a total trading volume of 7.59 billion yuan and a turnover rate of 3.18% [1] - Shuyou Shen operates in the biopharmaceutical sector, focusing on the research and production of innovative drugs, including monoclonal antibodies and other innovative therapies, particularly for neurological and immune system diseases [1] Group 2 - On August 12, the stock price of Shuyou Shen experienced a rapid decline of over 2% within the first five minutes of trading, indicating significant short-term market volatility [1] - In terms of capital flow, on August 12, there was a net outflow of 102 million yuan from main funds, accounting for 0.43% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 146 million yuan, representing 0.62% of the circulating market value [1]